Shots:
- ViiV Healthcare (owned by GSK with Pfizer & Shionogi as shareholders) has received EC’s approval for Vocabria (cabotegravir) combined with J&J’s Rekambys (rilpivirine) to treat HIV-1 in virologically suppressed adolescents (≥12yrs. & ≥35kg), following CHMP opinion in Dec 2024
- MAA was based on 24wks. data from ongoing P-I/II (MOCHA) trial evaluating the safety, tolerability & PK profile of Vocabria + Rekambys long-acting injections among 144 adolescents
- Study showed virological suppression (plasma HIV-1 RNA value <50c/mL) in 96.5% (139/144) at wk.24. Additionally, 99% (139/141) preferred long-acting injections over daily oral meds
Ref: GSK | Image: ViiV Healthcare
Related News:- ViiV Healthcare Reports the CHMP’s Positive Opinion of Vocabria Plus Rekambys for HIV treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
